

Helena Linardou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3787399/publications.pdf>

Version: 2024-02-01

51
papers

4,881
citations

279798

23
h-index

197818

49
g-index

51
all docs

51
docs citations

51
times ranked

8272
citing authors

#	ARTICLE	IF	CITATIONS
1	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 289-308.	1.1	173
2	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. <i>Clinical Lung Cancer</i> , 2021, 22, e180-e192.	2.6	15
3	First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. <i>Journal of Thoracic Oncology</i> , 2021, 16, 665-676.	1.1	30
4	A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The "LUNGFUL" Study. <i>Cancers</i> , 2021, 13, 3172.	3.7	6
5	Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	4.2	16
6	An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 93-102.	2.7	1
7	Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVER Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. <i>Cancers</i> , 2021, 13, 4621.	3.7	29
8	The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab. <i>Supportive Care in Cancer</i> , 2020, 28, 177-184.	2.2	4
9	The Role of CXCL13 and CXCL9 in Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e36-e53.	2.4	29
10	Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression $\geq 50\%$. <i>Journal of Immunotherapy</i> , 2020, 43, 299-306.	2.4	18
11	Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2438.	2.4	2
12	Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group. <i>ESMO Open</i> , 2020, 5, e000774.	4.5	20
13	Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score $\geq 50\%$ treated with front-line pembrolizumab. <i>Acta Oncologica</i> , 2020, 59, 1058-1063.	1.8	31
14	Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. <i>Oral Diseases</i> , 2020, 26, 955-966.	3.0	43
15	Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group. <i>Anticancer Research</i> , 2020, 40, 2095-2106.	1.1	2
16	Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9500-9500.	1.6	42
17	Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1 $> 50\%$.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21651-e21651.	1.6	4
18	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. <i>Oncotarget</i> , 2020, 11, 1-14.	1.8	1

#	ARTICLE	IF	CITATIONS
19	Genotyping <i>KRAS</i> and <i>EGFR</i> Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 531-541.	2.0	8
20	Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab. <i>ESMO Open</i> , 2019, 4, e000441.	4.5	3
21	Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors. <i>Melanoma Research</i> , 2019, 29, 428-434.	1.2	0
22	Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. <i>Clinical Breast Cancer</i> , 2019, 19, 113-125.e4.	2.4	8
23	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 $\geq 50\%$ who progress on first-line immunotherapy: real-world data from a European cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4972-4981.	1.4	35
24	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 378, 2093-2104.	27.0	2,469
25	Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study. <i>Targeted Oncology</i> , 2018, 13, 715-724.	3.6	19
26	Toxicity management of immunotherapy for patients with metastatic melanoma. <i>Annals of Translational Medicine</i> , 2016, 4, 272-272.	1.7	92
27	Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. <i>Annals of Translational Medicine</i> , 2016, 4, 268-268.	1.7	16
28	Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?. <i>Cancer Treatment Reviews</i> , 2016, 48, 8-19.	7.7	26
29	Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin–vinblastine–temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG). <i>Anticancer Research</i> , 2015, 35, 1105-13.	1.1	8
30	Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. <i>Anticancer Research</i> , 2015, 35, 4023-36.	1.1	8
31	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. <i>Breast</i> , 2014, 23, 234-243.	2.2	26
32	Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. <i>BMC Cancer</i> , 2013, 13, 163.	2.6	27
33	Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG). <i>PLoS ONE</i> , 2013, 8, e70634.	2.5	15
34	The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. <i>Breast Cancer Research</i> , 2012, 14, R145.	5.0	34
35	All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. <i>Cancer Treatment Reviews</i> , 2011, 37, 221-233.	7.7	45
36	Targeting angiogenesis for the treatment of advanced melanoma. <i>Oncology Reviews</i> , 2011, 5, 167-176.	1.8	2

#	ARTICLE	IF	CITATIONS
37	A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. <i>BMC Medicine</i> , 2010, 8, 3.	5.5	42
38	Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study. <i>Journal of Oncology</i> , 2010, 2010, 1-10.	1.3	18
39	Somatic <i>EGFR</i> Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 291-303.	7.0	134
40	<i>TP53</i> Arg72Pro Polymorphism and Colorectal Cancer Risk: A Systematic Review and Meta-Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1840-1847.	2.5	41
41	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 352-366.	27.6	207
42	Assessment of somatic <i>k-RAS</i> mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2008, 9, 962-972.	10.7	709
43	Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation. <i>Cancer Investigation</i> , 2008, 26, 784-793.	1.3	66
44	Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database. <i>Journal of Thoracic Oncology</i> , 2008, 3, 832-839.	1.1	137
45	Gastrointestinal solitary metastases from squamous cell lung cancer. <i>Lung Cancer</i> , 2007, 55, 251-252.	2.0	1
46	The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2006, 106, 297-303.	4.1	78
47	Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. <i>Urology</i> , 2004, 64, 479-484.	1.0	108
48	Therapeutic anticancer antibodies. <i>Expert Opinion on Therapeutic Patents</i> , 2003, 13, 177-222.	5.0	1
49	Non-cancer therapeutic antibodies. <i>Expert Opinion on Therapeutic Patents</i> , 2002, 12, 401-417.	5.0	1
50	A recombinant cytotoxic chimera based on mammalian deoxyribonuclease-I. , 2000, 86, 561-569.		15
51	Breast cancer in women with palpable breast cysts. <i>Lancet</i> , The, 1999, 354, 677.	13.7	16